Page 1 | Search Results | Diabetes | American Diabetes Association

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Glucagon Clearance is Decreased in Chronic Kidney Disease, but Preserved in Liver Cirrhosis

Magnus F. G. Grøndahl, Andreas H. Lange, Malte P. Suppli, Jonatan I. Bagger, Mira Thing, Lise L. Gluud, Dea H. Kofod, Mads Hornum, Gerrit Van Hall, Samuel A.J. Trammell, Trisha J. Grevengoed, Bolette Hartmann, Jens J. Holst, Tina Vilsbøll, Mikkel B. Christensen, Asger B. Lund, Filip K. Knop

Diabetes db240305

https://doi.org/10.2337/db24-0305

Published: 25 July 2024

View article titled, Glucagon Clearance is Decreased in Chronic Kidney Disease, but Preserved in Liver Cirrhosis

Meeting Abstracts

1613-P: Feasibility of Time-Restricted Eating in the Treatment of Type 2 Diabetes—The RESET2 Pilot Study

ANNE-DITTE TERMANNSEN, ANNEMARIE R. VARMING, GITTE S.H. STAGE HANSEN, NATASJA BJERRE, FREDERIK PERSSON, JONATAN I. BAGGER, SR., NILS B. JØRGENSEN, NANA F. HEMPLER, KRISTINE FAERCH, JONAS S. QUIST

Diabetes 2023;72(Supplement_1):1613-P

https://doi.org/10.2337/db23-1613-P

Published: 20 June 2023

View article titled, 1613-P: Feasibility of Time-Restricted Eating in the Treatment of Type 2 Diabetes—The RESET2 Pilot Study

Meeting Abstracts

244-OR: Signs of Glucagon Resistance after a Two-Week Hypercaloric Diet Intervention

MALTE P. SUPPLI, JONATAN I. BAGGER, SR., JENS J. HOLST, FILIP K. KNOP

Diabetes 2023;72(Supplement_1):244-OR

https://doi.org/10.2337/db23-244-OR

Published: 20 June 2023

View article titled, 244-OR: Signs of Glucagon Resistance after a Two-Week Hypercaloric Diet Intervention

Journal Articles

Glucagon Clearance Is Preserved in Type 2 Diabetes

Magnus F.G. Grøndahl, Asger B. Lund, Jonatan I. Bagger, Tonny S. Petersen, Nicolai J. Wewer Albrechtsen, Jens J. Holst, Tina Vilsbøll, Mikkel B. Christensen, Filip K. Knop

Diabetes 2022;71(1):73–82

https://doi.org/10.2337/db21-0024

Published: 26 October 2021

View article titled, Glucagon Clearance Is Preserved in Type 2 Diabetes

Meeting Abstracts

1192-P: Robust Arginine-Stimulated Glucagon Secretion in Patients with Type 1 Diabetes Independent of Diabetes Duration, Age, HbA1c, and Beta-Cell Secretory Capacity

JULIE WARNØE, NICKLAS J. JOHANSEN, ASGER LUND, JONATAN I. BAGGER, NICOLAI J. WEWER ALBRECHTSEN, SR., BOLETTE HARTMANN, JENS J. HOLST, TINA VILSBØLL, HENRIK U. ANDERSEN, THOMAS F. DEJGAARD, FILIP K. KNOP

Diabetes 2021;70(Supplement_1):1192-P

https://doi.org/10.2337/db21-1192-P

Published: 01 June 2021

View article titled, 1192-P: Robust Arginine-Stimulated Glucagon Secretion in Patients with Type 1 Diabetes Independent of Diabetes Duration, Age, HbA1c, and Beta-Cell Secretory Capacity

Meeting Abstracts

45-OR: Hypoglycemia, Glycemic Variability, and Risk of Cardiac Arrhythmias in Insulin-Treated Patients with Type 2 Diabetes

ANDREAS ANDERSEN, JONATAN I. BAGGER, SAMUEL K. SØRENSEN, MARIA POMPEA ANTONIA BALDASSARRE, ULRIK PEDERSEN-BJERGAARD, JULIE FORMAN, GUNNAR GISLASON, TOMMI B. LINDHARDT, FILIP K. KNOP, TINA VILSBØLL

Diabetes 2021;70(Supplement_1):45-OR

https://doi.org/10.2337/db21-45-OR

Published: 01 June 2021

View article titled, 45-OR: Hypoglycemia, Glycemic Variability, and Risk of Cardiac Arrhythmias in Insulin-Treated Patients with Type 2 Diabetes

Journal Articles

Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects

Jonatan I. Bagger, Magnus F.G. Grøndahl, Asger Lund, Jens J. Holst, Tina Vilsbøll, Filip K. Knop

Diabetes 2021;70(6):1347–1356

https://doi.org/10.2337/db20-0998

Published: 15 March 2021

View article titled, Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects

Meeting Abstracts

160-OR: Acute Changes in Plasma Glucose Have Impact on Left Ventricular Systolic Function in Insulin-Treated Patients with Type 2 Diabetes

ANDREAS ANDERSEN, PETER G. JØRGENSEN, JONATAN I. BAGGER, SR., MARIA POMPEA ANTONIA BALDASSARRE, MIKKEL B. CHRISTENSEN, KIRSTEN U. ABELIN, ULRIK PEDERSEN-BJERGAARD, JENS J. HOLST, TOMMI B. LINDHARDT, FILIP K. KNOP, TINA VILSBØLL

Diabetes 2020;69(Supplement_1):160-OR

https://doi.org/10.2337/db20-160-OR

Published: 01 June 2020

View article titled, 160-OR: Acute Changes in Plasma Glucose Have Impact on Left Ventricular Systolic Function in Insulin-Treated Patients with Type 2 Diabetes

Journal Articles

Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis

Malte P. Suppli, Jonatan I. Bagger, Asger Lund, Mia Demant, Gerrit van Hall, Charlotte Strandberg, Merete J. Kønig, Kristoffer Rigbolt, Jill L. Langhoff, Nicolai J. Wewer Albrechtsen, Jens J. Holst, Tina Vilsbøll, Filip K. Knop

Diabetes 2020;69(6):1090–1099

https://doi.org/10.2337/db19-0715

Published: 23 January 2020

View article titled, Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis

Includes: Supplementary data

Meeting Abstracts

1721-P: Effect of the TCF7L2 Variant rs7903146 T Allele on the Incretin Effect in Individuals with Normal Glucose Tolerance or Type 2 Diabetes

DAVID S. MATHIESEN, ASGER B. LUND, KATRINE BAGGE HANSEN, ANDERS JUNKER, THOMAS IDORN, MADS HORNUM, ANNA JONSSON, TORBEN HANSEN, TINA VILSBØLL, JONATAN I. BAGGER, FILIP K. KNOP

Diabetes 2019;68(Supplement_1):1721-P

https://doi.org/10.2337/db19-1721-P

Published: 01 June 2019

View article titled, 1721-P: Effect of the TCF7L2 Variant rs7903146 T Allele on the Incretin Effect in Individuals with Normal Glucose Tolerance or Type 2 Diabetes

Meeting Abstracts

Glucagon Resistance at the Level of Amino Acid Turnover and Ureagenesis in Obese Subjects with Hepatic Steatosis

MALTE P. SUPPLI, JONATAN I. BAGGER, ASGER B. LUND, NICOLAI J. WEWER ALBRECHTSEN, JENS J. HOLST, TINA VILSBØLL, FILIP K. KNOP

Diabetes 2018;67(Supplement_1):147-OR

https://doi.org/10.2337/db18-147-OR

Published: 01 July 2018

View article titled, Glucagon Resistance at the Level of Amino Acid Turnover and Ureagenesis in Obese Subjects with Hepatic Steatosis

Meeting Abstracts

Clinical Features and Hepatic Molecular Characteristics in NAFLD and NASH Patients Compared to Normal Weight Healthy Individuals

MALTE P. SUPPLI, KRISTOFFER RIGBOLT, SANNE VEIDAL, SARA HEEBØLL, MIA DEMANT, JONATAN I. BAGGER, ASGER B. LUND, TINA VILSBØLL, NIELS VRANG, JACOB JELSING, FILIP K. KNOP

Diabetes 2018;67(Supplement_1):260-LB

https://doi.org/10.2337/db18-260-LB

Published: 01 July 2018

View article titled, Clinical Features and Hepatic Molecular Characteristics in NAFLD and NASH Patients Compared to Normal Weight Healthy Individuals

Journal Articles

Erratum. Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes 2016;65: 585–597

Asger Lund, Jonatan I. Bagger, Nicolai J. Wewer Albrechtsen, Mikkel Christensen, Magnus Grøndahl, Bolette Hartmann, Elisabeth R. Mathiesen, Carsten P. Hansen, Jan H. Storkholm, Gerrit van Hall, Jens F. Rehfeld, Daniel Hornburg, Felix Meissner, Matthias Mann, Steen Larsen, Jens J. Holst, Tina Vilsbøll, Filip K. Knop

Diabetes 2016;65(6):1752

https://doi.org/10.2337/db16-er06

Published: 18 May 2016

View article titled, Erratum. Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes 2016;65: 585–597

Journal Articles

Evidence of Extrapancreatic Glucagon Secretion in Man

Diabetes 2016;65(3):585–597

https://doi.org/10.2337/db15-1541

Published: 15 December 2015

View article titled, Evidence of Extrapancreatic Glucagon Secretion in Man

Includes: Supplementary data

Journal Articles

Incretin Effect and Glucagon Responses to Oral and Intravenous Glucose in Patients With Maturity-Onset Diabetes of the Young—Type 2 and Type 3

Signe H. Østoft, Jonatan I. Bagger, Torben Hansen, Oluf Pedersen, Jens J. Holst, Filip K. Knop, Tina Vilsbøll

Diabetes 2014;63(8):2838–2844

https://doi.org/10.2337/db13-1878

Published: 17 July 2014

View article titled, Incretin Effect and Glucagon Responses to Oral and Intravenous Glucose in Patients With Maturity-Onset Diabetes of the Young—Type 2 and Type 3

Includes: Supplementary data

NARROW

Glucagon Clearance is Decreased in Chronic Kidney Disease, but Preserved in Liver Cirrhosis

1613-P: Feasibility of Time-Restricted Eating in the Treatment of Type 2 Diabetes—The RESET2 Pilot Study

244-OR: Signs of Glucagon Resistance after a Two-Week Hypercaloric Diet Intervention

Glucagon Clearance Is Preserved in Type 2 Diabetes

1192-P: Robust Arginine-Stimulated Glucagon Secretion in Patients with Type 1 Diabetes Independent of Diabetes Duration, Age, HbA1c, and Beta-Cell Secretory Capacity

45-OR: Hypoglycemia, Glycemic Variability, and Risk of Cardiac Arrhythmias in Insulin-Treated Patients with Type 2 Diabetes

Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects

160-OR: Acute Changes in Plasma Glucose Have Impact on Left Ventricular Systolic Function in Insulin-Treated Patients with Type 2 Diabetes

Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis

1721-P: Effect of the TCF7L2 Variant rs7903146 T Allele on the Incretin Effect in Individuals with Normal Glucose Tolerance or Type 2 Diabetes

Glucagon Resistance at the Level of Amino Acid Turnover and Ureagenesis in Obese Subjects with Hepatic Steatosis

Clinical Features and Hepatic Molecular Characteristics in NAFLD and NASH Patients Compared to Normal Weight Healthy Individuals

Erratum. Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes 2016;65: 585–597

Evidence of Extrapancreatic Glucagon Secretion in Man

Incretin Effect and Glucagon Responses to Oral and Intravenous Glucose in Patients With Maturity-Onset Diabetes of the Young—Type 2 and Type 3

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only